The first VR solution in MedTech

* working prototype


7 days 6 hours 45 minutes
play video

VR MED Today

VR MED software and hardware complex for screening in the field of Ophthalmology was tested in the Institute of Eye Diseases of the Academy of Sciences Russia and FH Aachen University of applied science, Germany. Today, the VR helmet is capable of replacing 40% of all instrument functionality ophthalmology room, having a cost of 6 times less than the cost equipment "Golden Standard".

Multifunctional Medical headset

  • Ergonomic design
  • Examination of patients with disabilities
  • Functioning alpha version
  • Mobility of the device
  • Visual field analyzer for the diagnosis of glaucoma
  • Patented technology
  • Vision Field Analyzer

    The VR MED headset provides vision field analysis to allow physicians to diagnosis early-stage glaucoma. Preliminary testing of the headset, completed at the FH Aachen University of Applied Sciences, has confirmed the uniqueness and innovation of this product. Now the equipment is undergoing testing at the Institute of Eye Diseases at the Russian Academy of Sciences.

  • Portability

    The VR MED headset is mobile. To use it, the clinician needs only the headset itself, and the notebook that it will be plugged into. Its weight (0.4 kg, about one pound) and compact dimensions add to its ease of transport. It can be used in mobile medical units, small stationary clinics and with telemedicine set-ups.

  • Ergonomic Design

    VR MED is integrated into a headset with ergonomic design, which, in contrast with its competitors, provides a higher degree of accuracy in rapid-speed eye-tracking. This gives the headset versatility for use in various medical settings.

All you need to produce results: put in the appropriate software and configure the system

VR MED is the first medical device in the world to employ VR technology for a wide range of uses. It has similar success not only in ophthalmology, but also neurology and rehabilitation. All you need for the transformation is to put in the required software and configure the system. There is no need to change the device itself. Just one set of equipment covers a large part of the clinic’s needs with VR technology.

Description of the platform and its necessity for the development of VR MED

Data storage, transport, exchange and sale.

All data acquired through medical research has a high value toward further medical developments. The accumulation of data by users through decentralized platforms allows research centers to obtain data required for research. This data is also necessary in statistics-keeping and in development of insurance programs.

Assistance with development of new software solutions using the headset – approval, testing, market introduction through the internal platform for procurement of investment.

This fully-functioning medical device, needing no additional testing or development, will help a large number of researchers bring to life new diagnostic and treatment solutions for patients – based on VR technology.

In order to bring projects forward, developers will be required to go through the VR MED platform for approval of a new software for the device, for investment in the device and to introduce the finished product to the market. Since the device does not require further testing, time is saved toward new solutions in digital medicine.

Sales of new successful software solutions to medical centers.

Developers will provide new successful software solutions to medical centers and create improved outcomes through the platform. All users of VR MED will be able to continuously upload new content. This will increase the usefulness of the device and capture new avenues of research.

  • Reserch centers and medical

    Medical centers will be able through the platform to acquire the device and program support at an affordable cost, with access to program updates. The goal is to widen the functionality of the device and to accumulate patient data for distribution among token holders – the center’s developers and researchers.On the platform, research centers can access patient data for research in various spheres of medicine, and also invest tokens in new research projects under development.

  • Developers

    For researchers, the platform opens the opportunity to conduct research using already collected data, saving time and material costs. After approval from peer reviews or experts, developers can publish their projects for crowdfunding from platform investors and use the funding to complete their project and sell to interested platform users (medical centers).

  • Investors

    Investors can invest in the platform one time and benefit from the sale of tokens increasing in value, or alternatively can invest tokens in new projects and benefit from further developments.

Token Sale

About VRMD Token

Token ERC 20 Protocol
Quantity 30 000 000 Tokens
Price 0.25 USD = 1 Token VRMD
Buy with


Hard cap: $5,000,000
Soft cap: $1,000,000

Token and Budget distribution:

20,000,000 VRMD – Crowd Sale
4,000,000 VRMD – Team, Bounty, Marketing
6,000,000 VRMD – Reserve

Investment Attractiveness

0,25$ 0,5$ 1$ 5 clinics and research centers in the Russia 25 clinics and research centers in the world 100 clinics and research centers in the world Clinics and research centers in the world With the increase of number of clinics using the VR MED headset the price of token will grow.

VRMD Token is an internal currency platform which allows holders to:

  • Acquire a product and access to services for a reduced price in comparison to with fiat currency
  • Acquire access to update software, widen the functional capabilities of the headset, buying and selling data.
  • Take part in fundraising for new medical developments for the VR MED headset Growth of demand for the tokens will depend on growth of demand for the device and updates

Gadget Features

VR MED is unique in its functional capabilities. One device contains the power to collect data in more than one sphere of medicine.

10,8 bln 58 bln 17,5 bln Ophthalmology Rehabilitation Neurology
  • The volume of the market of ophthalmology by 2021 will be 58 billion US dollars. Part of which will be the VR solution. At the moment, VR MED can potentially occupy about 10% of the market.
  • The market volume of devices for neurology by 2022 will amount to 10.8 billion US dollars. VR MED can potentially take up to 20% of solutions in this area.
  • The volume of the device market for rehabilitation measures by 2025 is planned at the level of 17.5 billion US dollars.
    The share of VR MED can be up to 15%.


Before ICO

  • Start of the development of the VR headset and programming suitable for medical use.

  • Patent granted in Russia.
    Start of process to receive international patents

  • Creation of pilot model of equipment and software for screening for early detection of glaucoma and other conditions with peripheral vision defects.
    Successful experimental outcomes in the Institute of Eye Diseases at the Russia Academy of Sciences

  • Participation at international presentations in Lisbon and Bahrain. Introduction of the device

  • Successful approval process for the device and software at the FH Aachen University of Applied Sciences

  • Development of the Alpha version of the device, with the capability of providing solutions in ophthalmology (measurement of peripheral vision, diagnosis of glaucoma markers)

After ICO

  • Development of the device final version
    (technical and usage fine-tuning), construct improvements

  • Standard ISO 12866-2011. Industrial design development

  • Certification of software “Perimeter”: Creation of a universal design for diagnosis of a range of visual functions (through early diagnosis of glaucoma and other peripheral vision field defects)

  • Entrance to the world market: Undergo approval process in India and China clinics; obtain international ISO certification

  • Upload of users’ data to the platform. Distribution of the device in the European Union, Russia and Asia;
    Launch of decentralized platform;
    The 100% functional Perimeter becomes the “gold standard” in ophthalmic diagnosis

  • Widening of device functionality to include usage in neurology and rehabilitation


  • Levon Grigoryan
    Levon Grigoryan

    CEO, Co-founder, patent author

  • Alex Sundukov
    Alex Sundukov

    COO, SAP, HP, PwC, Philips

  • Ilya Panenkov
    Ilya Panenkov

    Lead Medical Business Developer

  • Dmitriy Mikhailov
    Dmitriy Mikhailov

    Investment Director, Co-founder Aktivo, MTS

  • Alexey Ermolaev
    Alexey Ermolaev

    Medical leader, MD, Co-founder, Author of patents

  • Grigor Grigoryan
    Grigor Grigoryan

    CTO, Co-founder, Patent author

  • Aleksandr Zayanchukovskiy
    Aleksandr Zayanchukovskiy

    Lead Design Engineer, Model Specialist

  • Denis Ovod
    Denis Ovod

    VR developer, Graphics Programmer Red Machine LLC, W.E.L.L., Diamond Scent Ltd, BioLink

  • Anton Shokurov
    Anton Shokurov

    Lead Engineer, Mathematician, Algorithm Developer

  • Andrey Pravdivtsev
    Andrey Pravdivtsev

    Optical Designer, Optical system modeling

  • Kseniia Deina
    Kseniia Deina

    SMM manager

  • Alex Fominyh
    Alex Fominyh

    Senior engineer

  • Ekaterina Gromyko
    Ekaterina Gromyko

    Pr & Marketing specialist

  • Ekaterina Medvedeva
    Ekaterina Medvedeva

    Marketing director


  • Ina Glueck
    Ina Glueck

    International Business Development, Bionesty Ltd., Representative of VR MED in EU, UK

  • Konstantin Kotlyar
    Konstantin Kotlyar

    PhD, Professor of biomedical engineering FH Aachen University of Applied Sciences

  • Alexey Antonov
    Alexey Antonov

    MD,Ph.D., leading expert of Research Institute of Eye Diseases of Russian Academy of Scienses




Sign in Telegram